Santhera Pharmaceuticals Holding AG (SANN) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Santhera Pharmaceuticals Holding AG (Santhera) develops and commercializes novel pharmaceutical products indicated for patients with mitochondrial and neuromuscular diseases. It specifically focuses in the area of neuromuscular and neuro-ophthalmological conditions. The companys lead product candidate, Raxone (idebenone), is developed for the treatment of Lebers hereditary optic neuropathy (LHON). Raxone is also investigated for other diseases such as Duchenne muscular dystrophy and primary progressive multiple sclerosis. Santheras pipeline also includes other compounds, namely, omigapil for congenital muscular dystrophies. It operates along with its subsidiaries located in Switzerland, Germany, Canada, Finland and the US. Santhera is headquartered in Pratteln, Switzerland.

Santhera Pharmaceuticals Holding AG (SANN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 4
List of Figures 4
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Santhera Pharma Enters into Distribution Agreement with Pharmathen Pharma 10
Licensing Agreements 11
Santhera Pharma Enters into Licensing Agreement with Polyphor 11
Equity Offering 12
Santhera Pharma Raises USD53.3 Million in Private Placement of Shares 12
Santhera Pharma Raises USD28 Million through Private Placement of Shares 13
Santhera Pharma Raises USD15 Million in Public Offering of Shares 14
Santhera Pharma Completes Private Placement Of Shares For US$1 Million 15
Santhera Pharma Announces Private Placement Of Units For US$11 Million 16
Debt Offering 17
Santhera Pharma Raises USD60.2 Million in Public Offering of 5% Bonds Due 2022 17
Santhera Pharmaceuticals Holding AG - Key Competitors 18
Santhera Pharmaceuticals Holding AG - Key Employees 19
Santhera Pharmaceuticals Holding AG - Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Financial Announcements 21
Mar 20, 2018: Santhera Reports Solid Top-line Growth in 2017 and Reiterates its Strategy to Obtain Approval for Idebenone in Duchenne Muscular Dystrophy 21
Jan 29, 2018: Santhera Reports Preliminary Key Financial Figures for 2017 and Provides Corporate Update 23
Sep 05, 2017: Santhera Announces Financial Results for the First Half-Year 2017 and Reports Commercial and Development Progress 25
Mar 07, 2017: Santhera Delivered Solid Performance in 2016 and Advances All Programs 26
Jan 26, 2017: Santhera Reports Preliminary Key Financial Figures For 2016 And Provides Corporate Update 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List Of Tables

List of Tables
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Santhera Pharmaceuticals Holding AG, Deals By Therapy Area, 2012 to YTD 2018 8
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Santhera Pharma Enters into Distribution Agreement with Pharmathen Pharma 10
Santhera Pharma Enters into Licensing Agreement with Polyphor 11
Santhera Pharma Raises USD53.3 Million in Private Placement of Shares 12
Santhera Pharma Raises USD28 Million through Private Placement of Shares 13
Santhera Pharma Raises USD15 Million in Public Offering of Shares 14
Santhera Pharma Completes Private Placement Of Shares For US$1 Million 15
Santhera Pharma Announces Private Placement Of Units For US$11 Million 16
Santhera Pharma Raises USD60.2 Million in Public Offering of 5% Bonds Due 2022 17
Santhera Pharmaceuticals Holding AG, Key Competitors 18
Santhera Pharmaceuticals Holding AG, Key Employees 19
Santhera Pharmaceuticals Holding AG, Subsidiaries 20

List Of Figures

List of Figures
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Santhera Pharmaceuticals Holding AG - Mergers and Acquisitions (MandA), Partnerships and Alliances and Investment Report

Santhera Pharmaceuticals Holding AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportThe Santhera Pharmaceuticals Holding AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes

USD 350 View Report

Santhera Pharmaceuticals Holding AG (SANN) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Santhera Pharmaceuticals Holding AG (Santhera) develops and commercializes novel pharmaceutical products indicated for patients with mitochondrial and neuromuscular diseases. It specifically focuses in the area of neuromuscular and neuro-ophthalmological conditions.

USD 250 View Report

Adgero Biopharmaceuticals Holdings Inc - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Adgero Biopharmaceuticals Holdings Inc (Adgero), formerly Adgero Biopharmaceuticals Inc is a biopharmaceutical company that develops proprietary late stage photodynamic therapy platform for the treatment of oncology indications. The companys pipeline

USD 250 View Report

Santhera Pharmaceuticals Holding AG - Mergers and Acquisitions (MandA), Partnerships and Alliances and Investment Report

Santhera Pharmaceuticals Holding AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportThe Santhera Pharmaceuticals Holding AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes

USD 350 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available